Salute e Benessere

Maxim Group initiates the coverage of the CROSSJECT share with a BUY…

Press releaseMaxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00Dijon, France 03 June 2025 (07.30 CET) -- CROSSJECT(ISIN: FR0011716265; Euronext: ALCJ), the specialty pharma company in advanced phases of development and registration for ZEPIZURE® in adults, is informing about the recent initiation of coverage by Maxim Group, the US brokerage firm dedicated to biopharmaceutical companies and other emerging growth and...
Nasdaq GlobeNewswire
03/06/2025

Addex Convenes Annual General Meeting 2025

Geneva, Switzerland, June 3, 2025- Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2025 Annual General Meeting will take place on Tuesday June 24, 2025, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am). Agenda 1. Approval of the Annual Report, the Annual...
Nasdaq GlobeNewswire
03/06/2025

Roche's Tecentriq combined with lurbinectedin shows significant survival benefit…

46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options 1 First Phase III study in ES-SCLC first-line maintenance to demonstrate clinically meaningful improvements in both progression-free and overall survival 2,3 Data were presented in an oral session at the 2025 ASCO Annual Meeting and simultaneously published inThe Lancet1,4 Basel, 3 June 2025...
Nasdaq GlobeNewswire
03/06/2025

Press Release: Rilzabrutinib granted orphan drug designation in the US for…

Rilzabrutinib granted orphan drug designation in the US for sickle cell diseaseFourth orphan drug designation for rilzabrutinib in rare diseasesUnder regulatory review in the US, the EU, and China in immune thrombocytopeniaParis, June 3, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, a novel, advanced, oral, reversible Bruton's tyrosine kinase (BTK) inhibitor that works via multi-immune modulation, to target a reduction in...
Nasdaq GlobeNewswire
03/06/2025

Angelman Syndrome Market to Witness Significant Growth Through 2034, Driven by…

The condition is typically identified by developmental delays that become apparent between 6 and 12 months of age. Both males and females are equally affected, with the Angelman syndrome prevalence estimated to be about 1 in 12,000 to 20,000 people in the general population. The condition is typically identified by developmental delays that become apparent between 6 and 12 months of age. Both males and females are equally affected, with the Angelman syndrome prevalence estimated to be about1...
PR Newswire
02/06/2025

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare…

Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and…
PR Newswire
02/06/2025

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates…

Media ReleaseCOPENHAGEN, Denmark; June 2, 2025 New data showed that rinatabart sesutecan (Rina-S ® ) 100 mg/m 2 led to a confirmed objective response rate (ORR) of 50.0 percent, including two complete responses (CR), and median duration of response (mDOR) was not reached after a median follow-up of 7.7 monthsContinued evaluation of single-agent Rina-S 100 mg/m 2in patients with advanced endometrial cancer (EC) is ongoing in the Phase 2 RAINFOL™-01 trial and will be...
Nasdaq GlobeNewswire
02/06/2025

Full Dose-Escalation Data Show Continued High Response Rates and Favorable…

Safety profile continues to be favorable, with the majority of patients remaining on treatment at data cutoff Safety profile continues to be favorable, with the majority of patients remaining on treatment at data cutoff FDA recently granted ISB 2001 Fast Track Designation NEW YORK , June 2, 2025 /PRNewswire/ -- Ichnos Glenmark Innovation (IGI), a global, fully integrated clinical-stage biotechnology company focused on developing multispecifics™ in oncology, today presented...
PR Newswire
02/06/2025

OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer…

OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer Two presentations at the American Society of Clinical Oncology (ASCO) 2025:TEDOPaM - Phase 2 first positive results in advanced pancreatic cancer: Oral communication presented by the French GERCOR Oncology Group, trial sponsor.ARTEMIA- I nternational pivotal Phase 3 study in Non-Small Lung Cancer (NSCLC): Trial in Progress. ...
Nasdaq GlobeNewswire
02/06/2025

CRISPR Market is expected to generate a revenue of USD 12.78 Billion by 2032…

The CRISPR market is witnessing rapid growth due to its potential to transform gene therapy, diagnostics, and agriculture. With widespread research and commercial interest, the market is poised to shape the future of genomic healthcare. The CRISPR market is witnessing rapid growth due to its potential to transform gene therapy, diagnostics, and agriculture. With widespread research and commercial interest, the market is poised to shape the future of genomic healthcare. Key Highlights of the...
PR Newswire
02/06/2025

Medical Flexible Packaging Market Size worth $27.72 billion, Globally, by 2030-…

For More Information and To Stay Updated on The Latest Developments in The Medical Flexible Packaging Industry, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=10472 For More Information and To Stay Updated on The Latest Developments in The Medical Flexible Packaging Industry, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=10472 Market Overview and Growth Trajectory: Medical Flexible Packaging Industry Growth:...
PR Newswire
02/06/2025

HLA Typing Market worth US$2.3 billion by 2030 with 6.0% CAGR |…

Browse in-depth TOC on "HLA Typing Market" Browse in-depth TOC on "HLA Typing Market" 350 - Tables 52 - Figures 300 - Pages By Based on Product & Service,the reagents & consumables segment dominated the HLA typing market. Increasing emphasis on organ, tissue, and stem cell transplants is driving the demand for precise Human Leukocyte Antigen (HLA) matching considerably. This, in turn, is fueling enhanced use of reagents and consumables required for molecular and...
PR Newswire
02/06/2025

Medical Sensors Market Growth Forecast worth $142.2 billion, Globally, by 2030-…

For More Information and To Stay Updated on The Latest Developments in The Medical Sensors Market Share, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=8610 For More Information and To Stay Updated on The Latest Developments in The Medical Sensors Market Share, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=8610 Market Overview and Growth Trajectory: Medical Sensors Market Growth: According to an exhaustive...
PR Newswire
02/06/2025

Alvotech Meets Investors and Presents at the Jefferies Global Healthcare…

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies Global Healthcare Conference 2025, which will be held in New York, New York June 3-5, 2025. Members of the management team will host one-on-one meetings at the conference. Dr. Balaji Prasad, Chief Strategy Officer will deliver a presentation with recent business updates at the conference on Thursday...
Nasdaq GlobeNewswire
02/06/2025

Orexo to present clinical data for OX640 at the EAACI Congress

In addition to the oral presentation, Orexo's SVP and Head of R&D, Robert Rönn, will present a scientific poster demonstrating detailed stability data for OX640. In addition to the oral presentation, Orexo's SVP and Head of R&D, Robert Rönn, will present a scientific poster demonstrating detailed stability data for OX640. "We look forward to attending this important congress. Thanks to our powder-based drug-delivery technology, AmorphOX®, we are able to present strong data from…
PR Newswire
02/06/2025

Philanthropists and Business Leaders Gather in NY and London to Support…

The events will take place at two times: on June 3, from 8:30 a.m. to 11:30 a.m., at The Africa Center in New York, and on June 10, from 9:00 a.m. to 11:30 a.m., at The Royal Institution in London. On these occasions, the work of the Kianda Foundation will be presented to philanthropic leaders and businesspeople committed to gender equity. The events will take place at two times: onJune 3, from8:30 a.m. to 11:30 a.m., at The Africa Center inNew York, and onJune 10, from9:00 a.m...
PR Newswire
02/06/2025

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; June 2, 2025 – Genmab A/S (Nasdaq: GMAB).On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025.The following transactions were executed under the program from May 26 to May 30, 2025: Trading PlatformNo...
Nasdaq GlobeNewswire
02/06/2025

SkylineDx Highlights Merlin Assay's Power to Predict Recurrence Risk of Head and…

"The Merlin Assay is a major advancement in personalized care for patients with head and neck melanoma," said Principal Investigator, Teresa Amaral MD, PhD "SLNB can be technically challenging in the head and neck region. Merlin offers a powerful alternative for clinicians to make informed decisions without subjecting patients to unnecessary and potentially complicated surgical procedures." "The Merlin Assay is a major advancement in personalized care for patients with…
PR Newswire
02/06/2025

Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its…

Presentation at the International Conference on Malignant Lymphoma (ICML) in Lugano on June 21SIDNEY is an ongoing Phase 2 trial of EO2463 in 48 indolent Non-Hodgkin Lymphoma (iNHL) patientsEnterome has held a positive Type-C meeting with FDA for EO2463 in iNHLEnterome to attend Jefferies Healthcare conference in New York (June 3-5)Paris, France – June 2, 2025 Enterome SA,a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer,will...
Nasdaq GlobeNewswire
02/06/2025

Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput…

"Analytical laboratories are under pressure to adapt to the complex needs of pharmaceutical organizations, and meet the increasing demand for PFAS testing driven by a rapidly evolving regulatory landscape," said James Hallam, Vice President, Liquid Chromatography-Mass Spectrometry, Waters Corporation. "The Xevo TQ Absolute XR design delivers up to a six-fold increase in performance robustness with unmatched sensitivity and resilience to contamination, significantly reducing…
PR Newswire
02/06/2025

Endo Champions Men's Health Month with Education, Awareness, and Outreach

Key components of the campaign include: Key components of the campaign include: "Men may not always be the strongest advocates for their own health, but with the right information and awareness, we can empower them to take a more active role in their well-being," saidJustin Mattice, Senior Vice President & General Manager, Branded Specialty at Endo. "At Endo, we offer a unique portfolio of men's health products and equip healthcare providers with tools and education so they…
PR Newswire
02/06/2025

Novonesis completes acquisition of dsm-firmenichs's share of the Feed Enzyme…

Novonesis has successfully completed the acquisition of dsm-firmenich's share of the Feed Enzyme Alliance following the satisfaction of all closing conditions. The acquisition was initially announced on February 11, 2025 (announcement No 2).Please read the full announcement in PDF. Attachment 2025_Closing_of_the_Feed_Enzyme_Alliance
Nasdaq GlobeNewswire
02/06/2025

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

~ Alignment with FDA continues to support Accelerated Approval pathway ~~ BLA submission planned for first quarter of 2026 ~~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, June02, 2025(GLOBE NEWSWIRE) --uniQureN.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today provided a regulatory update on AMT-130, its investigational gene therapy for the treatment of Huntington's...
Nasdaq GlobeNewswire
02/06/2025

Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico…

"Executing on our strategy of targeted acquisitions, Cialis® will expand our existing portfolio in the region and strengthen Grünenthal's Latin American business", says Gabriel Baertschi, CEO, Grünenthal. "In 2022, we acquired Nebido®, a long-acting treatment for testosterone deficiency, and with Cialis® we can continue to serve our existing customer base and foster our growth in key Latin American markets." "Executing on our strategy of targeted acquisitions, Cialis…
PR Newswire
02/06/2025
Altri  Comunicati